Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model

Breast Cancer Research and Treatment

Volumn 40, Issue 3, 1996, Pages 209-223

  Alonso, Daniel F ^a   Farías, Eduardo F ^a   Ladeda, Virginia ^a   Davel, Lilia ^a   Puricelli, Lydia ^a   Bal De Kier Joffé, Elisa ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Breast cancer; Fibronectin; Invasion; Mouse mammary tumor model; Protease inhibitors; Treatment; Urokinase

Indexed keywords

B 428; B 623; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ADIPOSE TISSUE; ANGIOGENESIS; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; DERMIS; ENZYME INHIBITION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; METASTASIS; MOUSE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUBCUTANEOUS TISSUE;

AMIDINES; AMILORIDE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DIURETICS; ENZYME INHIBITORS; FEMALE; FIBRINOLYSIS; FIBRONECTINS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; THIOPHENES; TRIAMTERENE; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029789744     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806809     Document Type: Article

References (48)

1. Mullins DE, Rohrlich ST: The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695: 177-214, 1983
2. Danø K. Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985
3. Mignati P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487-498, 1986
4. Blasi F, Vassalli J-D, Danø K: Urokinase-type plasminogen activator: proenzyme, receptors and inhibitors. J Cell Biol 104: 801-804, 1987
5. Laiho M, Keski-Oja J: Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 49: 2533-2553, 1989
6. Vassali J-D, Pepper MS: Membrane proteases in focus. Nature 370: 14-15, 1994
7. Møller LB: Structure and function of the urokinase receptor. Blood Coagul Fibrinol 4: 293-303, 1993
8. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619, 1983
9. Ossowski L: Plasminogen activator dependent pathway in the dissemination of human tumor cells in the chick embryo. Cell 52:321-328, 1988
10. Ossowski L, Russo-Payne H, Wilson EL: Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281, 1991
11. Pepper MS, Vassalli J-D, Montesano R, Orci L: Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 105: 2535-2541, 1987
12. Vassalli J-D, Bellin D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214: 187-191, 1987
13. Towle MJ, Lee A, Maduakor EC, Schwartz EC, Bridges AJ, Littlefield BA: Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 53: 2553-2559, 1993
14. Alonso DF, Farías EF, Puricelli L, Bal de Kier Joffé E: In vitro and in vivo effects of potassium-sparing diuretics in a urokinase-producing murine mammary adenocarcinoma model. Proc Am Assoc Cancer Res 35: 68, 1994 (Abstract)
15. Bal de Kier Joffé E, Puricelli L, Sacerdote de Lustig E: Modified adhesion behavior after in vitro passage of two related murine mammary adenocarcinomas with different metastatic ability. Invasion Metastasis 6: 302-312, 1986
16. Alonso DF, Farías EF, Bal de Kier Joffé E: Urokinase-type plasminogen activator activity released by clonal tumor cell populations isolated during the growth of a murine mammary adenocarcinoma. J Exp Clin Cancer Res 13: 211-216, 1994
17. Bal de Kier Joffé E, Puricelli L, Vidal MC, Sacerdote de Lustig E: Characterization of two murine mammary adenocarcinoma tumors with different metastatic ability. J Exp Clin Cancer Res 2: 151-160, 1983
18. Pereyra-Alfonso S, Solarz GR, Bal de Kier Joffé E: Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities. Clin Exp Metastasis 10: 395-401, 1992
19. Laemmli U: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970
20. Alonso DF, Farías EF, Bal de Kier Joffé E: Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. Cancer Lett 70: 181-187, 1993
21. Wun TC, Schleuning WD, Reich E: Isolation and characterization of urokinase from human plasma. J Biol Chem 257: 3276-3283, 1982
22. Saksela O: Radial caseinolysis in agarose: a simple method for detection of plasminogen activator in the presence of inhibitory substances and serum. Anal Biochem 111: 276-282, 1981
23. Jankum, J Maher VM, McCormick JJ: Malignant transformation of human fibroblast correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 51: 1221-1226, 1991
24. Maidorn RP, Cragoe EJ Jr, Tannock IF: Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. Br J Cancer 67: 297-303, 1993
25. Spahn H, Reuter K, Mutschler E, Gerok W, Knauf H: Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 33: 493-498, 1987
26. Sidky YA, Auerbach R: Lymphocyte-induced angiogenesis in tumor-bearing mice. Science 192: 1237-1238, 1976
27. Miguez M, Davel L, Sacerdote de Lustig E: Lymphocyte-induced angiogenesis: correlation with the metastatic incidence of two murine mammary adenocarcinomas. Invasion Metastasis 6: 313-320, 1986
28. Monte M, Davel L, Sacerdote de Lustig E: Inhibition of lymphocyte-induced angiogenesis by free radical scavengers. Free Radic Biol Med 17: 259-266, 1994
29. Pereyra-Alfonso S, Haedo A, Bal de Kier Joffé E: Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas. Int J Cancer 42: 59-63, 1988
30. Ossowski L: In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell suface-bound urokinase. J Cell Biol 107: 2437-2445, 1988
31. Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma carcinoma cell lines. Cancer Commun 3: 255-264, 1991
32. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T: Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610-3614, 1992
33. Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG: Endogenous receptor-bound urokinase mediates tissue invasion of the lung carcinoma cell lines A549 and Calu-1. Cancer Res 52: 3043-3047, 1992
34. Quigley JP, Gold LI, Schwimmer R, Sullivan LM: Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 84: 2776-2780, 1987
35. Gold LI, Rostagno A, Frangione B, Passalaris T: Localization of the cleavage sites on fibronectin following digestion by urokinase. J Cell Biochem 50: 441-452, 1992
36. Mangel WF: Better reception for urokinase. Nature 344: 488-489, 1990
37. Sato Y, Okamura K, Morimoto A, Hamanaka R, Hamaguchi K, Shimada T, Ono M, Kohno K, Sakata T, Kuwano M: Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp Cell Res 204: 223-229, 1993
38. Alonso DF, Bertolesi GE, Farías EF, Eiján AM, Bal de Kier Joffé E, Lauría de Cidre L: Antimetastatic effects associated with anticoagulant properties of heparin and chemically modified heparin species in a mouse mammary tumor model. Oncology Rep 3: 219-222, 1996
39. Olander JV, Bremer ME, Marasa JC, Feder J: Fibrin-enhanced endothelial cell organization. J Cell Physiol 125:1-9, 1985
40. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM: Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 57: 673-686, 1987
41. Constantini V, Zacharski LR: The role of fibrin in tumor metastasis. Cancer Metast Rev 11: 283-290, 1992
42. Ostrowski LE, Ahsan A, Suthar BP, Pagast P, Bain DL, Wong C, Patel A, Schultz RM: Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res 46: 4121-4128, 1986
43. Kellen JA, Mirakian JA, Kolin A: Antimetastatic effect of amiloride in an animal tumor model. Anticancer Res 8: 1373-1376, 1988
44. Colombi M, Rebessi L, Boiocchi M, Barlati S: Relationship between circulating plasminogen activators and tumor development in mice. Cancer Res 46: 5748-5753, 1986
45. Gunji Y, Gorelik E: Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 48: 5216-5221, 1988
46. Esumi N, Fan D, Fidler IJ: Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 51: 4549-4556, 1991
47. Hauert J, Nicoloso G, Schleuning W, Bachmann F, Schapira M: Plasminogen activator in dextran sulfate-activated euglobulin-fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood 4:994-999, 1989
48. Kohn EC, Liotta LA: Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55: 1856-1862, 1995